ENOCHIAN BIOSCIENCES INC (ENOB) Fundamental Analysis & Valuation

NASDAQ:ENOB • US29350E1047

Current stock price

0.7 USD
0 (0%)
At close:
0.7 USD
0 (0%)
After Hours:

This ENOB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ENOB Profitability Analysis

1.1 Basic Checks

  • In the past year ENOB has reported negative net income.
  • In the past year ENOB has reported a negative cash flow from operations.
ENOB Yearly Net Income VS EBIT VS OCF VS FCFENOB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • ENOB has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENOB Yearly ROA, ROE, ROICENOB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

  • ENOB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENOB Yearly Profit, Operating, Gross MarginsENOB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ENOB Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ENOB has more shares outstanding
  • Compared to 1 year ago, ENOB has a worse debt to assets ratio.
ENOB Yearly Shares OutstandingENOB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
ENOB Yearly Total Debt VS Total AssetsENOB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.97, we must say that ENOB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.97, ENOB is in line with its industry, outperforming 41.19% of the companies in the same industry.
  • There is no outstanding debt for ENOB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.97
ROIC/WACCN/A
WACCN/A
ENOB Yearly LT Debt VS Equity VS FCFENOB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M 100M 150M

2.3 Liquidity

  • ENOB has a Current Ratio of 0.33. This is a bad value and indicates that ENOB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ENOB has a worse Current ratio (0.33) than 98.14% of its industry peers.
  • A Quick Ratio of 0.33 indicates that ENOB may have some problems paying its short term obligations.
  • ENOB has a worse Quick ratio (0.33) than 97.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
ENOB Yearly Current Assets VS Current LiabilitesENOB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ENOB Growth Analysis

3.1 Past

  • ENOB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -149.93%.
EPS 1Y (TTM)-149.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENOB Yearly Revenue VS EstimatesENOB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 0 0 0 0 0

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENOB Valuation Analysis

4.1 Price/Earnings Ratio

  • ENOB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENOB Price Earnings VS Forward Price EarningsENOB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENOB Per share dataENOB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENOB Dividend Analysis

5.1 Amount

  • No dividends for ENOB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOB Fundamentals: All Metrics, Ratios and Statistics

ENOCHIAN BIOSCIENCES INC

NASDAQ:ENOB (8/4/2023, 8:00:53 PM)

After market: 0.7 0 (0%)

0.7

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)12-13
Inst Owners25.33%
Inst Owner Change-99.69%
Ins Owners31.21%
Ins Owner Change0%
Market Cap40.80M
Revenue(TTM)N/A
Net Income(TTM)-106.72M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS1.13
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z -2.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.13%
Cap/Depr(5y)277.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-149.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.81%
OCF growth 3YN/A
OCF growth 5YN/A

ENOCHIAN BIOSCIENCES INC / ENOB Fundamental Analysis FAQ

What is the fundamental rating for ENOB stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENOB.


What is the valuation status of ENOCHIAN BIOSCIENCES INC (ENOB) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENOCHIAN BIOSCIENCES INC (ENOB). This can be considered as Overvalued.


How profitable is ENOCHIAN BIOSCIENCES INC (ENOB) stock?

ENOCHIAN BIOSCIENCES INC (ENOB) has a profitability rating of 0 / 10.


What is the financial health of ENOCHIAN BIOSCIENCES INC (ENOB) stock?

The financial health rating of ENOCHIAN BIOSCIENCES INC (ENOB) is 3 / 10.